Figure 5
p65BTK inhibition affects growth and survival of colon cancer cells. (a) Time course showing Ibrutinib dose response (0, 0.01, 0.1, 1, 10, 20 μM Ibru) of colon carcinoma cell lines characterized by different genetic background; cell proliferation was determined every 24 h by MTT assay on cells incubated with Ibrutinib at the indicated concentrations; error bars show s.e.m.; data are the average of 3–5 independent experiments. Ibrutinib at 10 and 20 μ M significatively decreases cell growth in all cell lines *10 vs 0 μ M Ibru P<0.05; **20 vs 0 μ M Ibru: P<0.05. (b) Clonogenicity was assessed by seeding cells at low density and incubating them with the indicated doses of Ibrutinib for 10–12 days, at the end of which colonies were stained by crystal violet. (c) Cell viability was assessed after 72 h of treatment with the indicated concentration of Ibrutinib; crystal violet assay was performed to quantify viable cells; data are presented as fold change of the initial cell number obtained from 3 independent experiments; error bars show s.e.m. *10 vs 0 μ M Ibru: P<0.05; **20 vs 0 μ M Ibru: P<0.05; ***30 vs 0 μ M Ibru: P< 0.05.
